We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · August 17, 2020

Selinexor in Patients With Myelodysplastic Syndromes or Oligoblastic AML Refractory to Hypomethylating Agents

The Lancet Haematology


Additional Info

The Lancet Haematology
Safety and Activity of Selinexor in Patients With Myelodysplastic Syndromes or Oligoblastic Acute Myeloid Leukaemia Refractory to Hypomethylating Agents: A Single-Centre, Single-Arm, Phase 2 Trial
Lancet Haematol 2020 Aug 01;7(8)e566-e574, J Taylor, X Mi, AV Penson, SV Paffenholz, K Alvarez, A Sigler, SS Chung, RK Rampal, JH Park, EM Stein, MS Tallman, F Sen, M Gönen, O Abdel-Wahab, VM Klimek

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading